Underwriters partially exercise over-allotment option in Cadence public offering

Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that its underwriters partially exercised their over-allotment option in connection with its previously announced public offering that priced on November 11, 2010, by purchasing an additional 1,000,000 shares of its common stock at a public offering price of $8.00 per share. Including the over-allotment shares purchased, Cadence sold a total of 12,500,000 shares in the offering, resulting in expected aggregate gross proceeds to the company of $100 million.

Deutsche Bank Securities Inc. acted as sole book-running manager for the offering.  Leerink Swann LLC acted as co-lead manager, and JMP Securities, Wedbush PacGrow Life Sciences and Canaccord Genuity Inc. acted as co-managers for the offering.

The securities described above were offered by Cadence pursuant to shelf registration statements that had been previously filed with and become effective by rule or order of the Securities and Exchange Commission (the "SEC").  A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement also may be obtained from Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, Telephone number: (800) 503-4611, Email: [email protected].